Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Dual and Triple Agonists: The next generation of medications, such as Tirzepatide (which targets both GLP-1 and GIP receptors), are already demonstrating even greater efficacy for weight loss and blood sugar control
No finished-drug approval, no active IND, and no FDA-registered human clinical trials as of April 2026
The metabolic changes that occur during treatment, including improved insulin sensitivity and reduced inflammation, are generally beneficial
As GLP-1 medications become more widely used for metabolic health and weight management, interest in needle-free alternatives has surged
Courses available: Menopause Miniseries (Osteoporosis, Progesterone, Thyroid, Estrogen), Copper Toxicity, Mens Testosterone and more
US$ 22.61
US$ 21.45
US$ 23.45
US$ 24.15
US$ 25.07
US$ 22.18
US$ 25.63
